PHARMACY

Prasco announces executive changes

BY Allison Cerra

CINCINNATI — Generic drug maker Prasco Labs has named Christopher Arington its vice chairman and CEO.

In addition to Arington’s promotion, David Vucurevich was promoted to president and COO, David Furniss was named CFO and Chris Gilmore was appointed VP strategic business ventures.

The moves were announced by Prasco chairman E. Thomas Arington.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Shelley Moore joins BioPlus

BY Allison Cerra

ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has appointed a new regional director.

The company said that Shelley Moore will be responsible for business development in Tennessee. Moore, a registered nurse, brings six years of nursing experience, along with a career specialty in bleeding disorders, to her position at BioPlus.

"BioPlus’ best-in-class bleeding disorders program is a new high-touch intervention to provide care and support for the patient and caregiver, clear cost savings to the payer, and optimal clinical outcomes," BioPlus chief strategy officer Russell Gay said. "Shelley is leading our program in Tennessee using her many years of support in the community and her nursing skills to improve the quality of life for our patients."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Ranbaxy launches Caduet authorized generic

BY Alaric DeArment

PRINCETON, N.J. — Days after its launch of a generic version of Pfizer’s cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.

An authorized generic is a branded drug launched under its generic name at a reduced price, usually by a third-party company under contract with the original manufacturer, to coincide with the marketing of the Food and Drug Administration-approved generic.

Caduet had sales of $339 million during the 12-month period ended in September, according to IMS Health.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES